Amgen Financial Statements From 2010 to 2024

AMGN Stock  USD 294.53  4.63  1.60%   
Amgen financial statements provide useful quarterly and yearly information to potential Amgen Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Amgen financial statements helps investors assess Amgen's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Amgen's valuation are summarized below:
Gross Profit
19.9 B
Profit Margin
0.13
Market Capitalization
158.3 B
Enterprise Value Revenue
6.4458
Revenue
32.5 B
We have found one hundred twenty available fundamental signals for Amgen Inc, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Amgen's prevailing fundamentals against the trend between 2010 and 2024 to make sure the company can sustain itself down the road. As of the 25th of November 2024, Market Cap is likely to grow to about 121.6 B. Also, Enterprise Value is likely to grow to about 53.9 B

Amgen Total Revenue

29.6 Billion

Check Amgen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amgen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 B, Interest Expense of 3 B or Selling General Administrative of 5.8 B, as well as many indicators such as Price To Sales Ratio of 9.47, Dividend Yield of 0.0185 or PTB Ratio of 25.96. Amgen financial statements analysis is a perfect complement when working with Amgen Valuation or Volatility modules.
  
Check out the analysis of Amgen Correlation against competitors.

Amgen Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets102 B97.2 B65.5 B
Slightly volatile
Short and Long Term Debt Total67.8 B64.6 B34.3 B
Slightly volatile
Other Current Liabilities14.3 B13.6 B7.5 B
Slightly volatile
Total Current Liabilities19.3 B18.4 B10.8 B
Slightly volatile
Total Stockholder Equity12.3 B6.2 B15.3 B
Slightly volatile
Property Plant And Equipment Net3.6 B6.6 B4.8 B
Slightly volatile
Cash11.5 B10.9 B5.8 B
Slightly volatile
Non Current Assets Total70.2 B66.8 B36.4 B
Slightly volatile
Non Currrent Assets Other9.4 BB3.5 B
Slightly volatile
Cash And Short Term Investments10.5 B10.9 B19.3 B
Pretty Stable
Net Receivables8.3 B7.9 B3.9 B
Slightly volatile
Common Stock Shares Outstanding759.2 M538 M713.7 M
Slightly volatile
Liabilities And Stockholders Equity102 B97.2 B65.5 B
Slightly volatile
Non Current Liabilities Total76.2 B72.5 B39.8 B
Slightly volatile
Other Current Assets2.7 B1.9 B3.3 B
Slightly volatile
Total Liabilities95.5 B90.9 B50.5 B
Slightly volatile
Property Plant And Equipment Gross16.5 B15.7 B7.5 B
Slightly volatile
Total Current Assets15.2 B30.3 B27.9 B
Very volatile
Short Term DebtB1.6 B1.7 B
Very volatile
Inventory10 B9.5 B3.9 B
Slightly volatile
Accounts Payable1.7 B1.6 B1.1 B
Slightly volatile
Common Stock Total Equity27.1 B37.4 B29 B
Slightly volatile
Short Term Investments12.2 B10.9 B15.3 B
Pretty Stable
Capital Stock27.5 B33.1 B28.8 B
Slightly volatile
Common Stock27.5 B33.1 B28.8 B
Slightly volatile
Other Assets1.4 B2.5 B1.8 B
Pretty Stable
Long Term Debt66.3 B63.2 B32.6 B
Slightly volatile
Property Plant Equipment5.3 B6.2 BB
Slightly volatile
Good Will14.4 B18.6 B14.4 B
Slightly volatile
Intangible Assets34.3 B32.6 B14.6 B
Slightly volatile
Other Liabilities5.1 B9.1 B6.3 B
Slightly volatile
Long Term Debt Total29.9 B43 B29.5 B
Slightly volatile
Non Current Liabilities Other2.2 B2.3 B4.9 B
Very volatile
Long Term Investments810.9 M918.9 M709.2 M
Slightly volatile
Short and Long Term Debt1.5 B1.4 B1.5 B
Pretty Stable
Net Invested Capital52.2 B70.8 B53.9 B
Slightly volatile
Net Working Capital12 B11.9 B26.7 B
Slightly volatile

Amgen Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization4.3 B4.1 B2.1 B
Slightly volatile
Interest ExpenseB2.9 B1.3 B
Slightly volatile
Selling General Administrative5.8 B5.5 B4.6 B
Slightly volatile
Total Revenue29.6 B28.2 B21.4 B
Slightly volatile
Gross Profit20.7 B19.7 B16.8 B
Slightly volatile
Other Operating Expenses21.3 B20.3 B13.8 B
Slightly volatile
EBIT4.6 B7.9 B6.9 B
Slightly volatile
EBITDA5.4 B7.9 B8.5 B
Slightly volatile
Total Operating Expenses12.4 B11.8 B9.1 B
Slightly volatile
Income Before TaxB7.9 B6.6 B
Slightly volatile
Net Income7.1 B6.7 B5.6 B
Slightly volatile
Income Tax Expense830.4 M1.1 B1.2 B
Pretty Stable
Research Development2.9 B4.8 B3.7 B
Slightly volatile
Net Income Applicable To Common SharesB7.5 B5.6 B
Slightly volatile
Net Income From Continuing Ops6.4 B7.6 BB
Slightly volatile
Tax Provision1.4 B1.2 B1.5 B
Very volatile
Interest Income218.9 M230.4 M476.9 M
Slightly volatile
Selling And Marketing Expenses759.1 M647 M580 M
Slightly volatile
Reconciled Depreciation3.2 B3.6 B2.5 B
Slightly volatile
Non Recurring1.2 B1.4 B1.5 B
Slightly volatile

Amgen Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash FlowB7.6 BB
Slightly volatile
Depreciation4.3 B4.1 B2.3 B
Slightly volatile
Capital Expenditures663.6 M1.1 B713.4 M
Slightly volatile
End Period Cash Flow11.5 B10.9 B5.7 B
Slightly volatile
Dividends Paid2.9 B4.6 B2.8 B
Slightly volatile
Change To Operating Activities637.1 M1.2 B670.3 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.475.46616.2408
Pretty Stable
Dividend Yield0.01850.02960.0218
Slightly volatile
PTB Ratio25.9624.725712.0551
Slightly volatile
Days Sales Outstanding10810363.8389
Slightly volatile
Book Value Per Share10.2611.648620.7969
Slightly volatile
Stock Based Compensation To Revenue0.01860.01530.0166
Slightly volatile
Capex To Depreciation0.260.27320.7017
Slightly volatile
PB Ratio25.9624.725712.0551
Slightly volatile
EV To Sales9.897.377.1815
Very volatile
Inventory Turnover0.840.88793.5871
Slightly volatile
Net Income Per Share13.1812.55518.7809
Slightly volatile
Days Of Inventory On Hand217411261
Pretty Stable
Payables Turnover2.985.31514.054
Very volatile
Sales General And Administrative To Revenue0.30.19620.2814
Slightly volatile
Research And Ddevelopement To Revenue0.220.16970.1857
Slightly volatile
Capex To Revenue0.03750.03940.0735
Slightly volatile
Cash Per Share42.9640.912130.4752
Pretty Stable
Payout Ratio0.420.67830.4935
Slightly volatile
Days Payables Outstanding13168.672393.7521
Pretty Stable
Income Quality1.11.26111.602
Very volatile
ROE1.131.07780.5715
Slightly volatile
PE Ratio21.7922.940468.8928
Slightly volatile
Return On Tangible Assets0.120.14640.1465
Slightly volatile
Earnings Yield0.03020.04360.0475
Very volatile
Intangibles To Total Assets0.470.52770.4257
Slightly volatile
Current Ratio1.571.64923.8797
Slightly volatile
Receivables Turnover3.373.54956.1121
Slightly volatile
Graham Number60.2357.363959.3155
Pretty Stable
Shareholders Equity Per Share10.2611.648620.7969
Slightly volatile
Debt To Equity10.8910.36793.6753
Slightly volatile
Capex Per Share2.182.07851.1607
Slightly volatile
Revenue Per Share55.3352.691633.4518
Slightly volatile
Interest Debt Per Share13212656.2933
Slightly volatile
Debt To Assets0.70.66510.4882
Slightly volatile
Enterprise Value Over EBITDA16.1316.980825.7865
Slightly volatile
Price Earnings Ratio21.7922.940468.8928
Slightly volatile
Operating Cycle540514338
Slightly volatile
Price Book Value Ratio25.9624.725712.0551
Slightly volatile
Days Of Payables Outstanding13168.672393.7521
Pretty Stable
Dividend Payout Ratio0.420.67830.4935
Slightly volatile
Pretax Profit Margin0.250.27860.3007
Pretty Stable
Effective Tax Rate0.220.14490.1711
Very volatile
Company Equity Multiplier16.3715.58956.5078
Slightly volatile
Long Term Debt To Capitalization0.960.91020.6473
Slightly volatile
Total Debt To Capitalization0.960.9120.6586
Slightly volatile
Debt Equity Ratio10.8910.36793.6753
Slightly volatile
Quick Ratio1.081.13173.5559
Slightly volatile
Net Income Per E B T0.640.85510.8195
Pretty Stable
Cash Ratio0.570.5951.4539
Slightly volatile
Cash Conversion Cycle468445253
Slightly volatile
Days Of Inventory Outstanding217411261
Pretty Stable
Days Of Sales Outstanding10810363.8389
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.640.86871.3854
Slightly volatile
Price To Book Ratio25.9624.725712.0551
Slightly volatile
Fixed Asset Turnover2.284.27643.9815
Slightly volatile
Enterprise Value Multiple16.1316.980825.7865
Slightly volatile
Debt Ratio0.70.66510.4882
Slightly volatile
Price Sales Ratio9.475.46616.2408
Pretty Stable
Return On Assets0.120.06910.0862
Slightly volatile
Asset Turnover0.510.29020.3401
Slightly volatile
Net Profit Margin0.180.23830.2435
Pretty Stable
Gross Profit Margin0.650.70020.8065
Slightly volatile
Price Fair Value25.9624.725712.0551
Slightly volatile
Return On Equity1.131.07780.5715
Slightly volatile

Amgen Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap121.6 B115.8 B112.6 B
Slightly volatile
Enterprise Value53.9 B51.4 B52.7 B
Slightly volatile

Amgen Fundamental Market Drivers

Forward Price Earnings14.2857
Cash And Short Term Investments10.9 B

Amgen Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Amgen Financial Statements

Amgen investors utilize fundamental indicators, such as revenue or net income, to predict how Amgen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-79.2 M-83.2 M
Total Revenue28.2 B29.6 B
Cost Of Revenue8.5 B8.9 B
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.20  0.30 
Research And Ddevelopement To Revenue 0.17  0.22 
Capex To Revenue 0.04  0.04 
Revenue Per Share 52.69  55.33 
Ebit Per Revenue 0.28  0.26 

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.61A Agilent Technologies Earnings Call TodayPairCorr
  0.79ME 23Andme HoldingPairCorr
  0.7VALN Valneva SE ADRPairCorr
  0.8JNJ Johnson Johnson Fiscal Year End 28th of January 2025 PairCorr

Moving against Amgen Stock

  0.46MDGL Madrigal PharmaceuticalsPairCorr
  0.41KZR Kezar Life SciencesPairCorr
  0.39RNXT RenovoRxPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.621
Dividend Share
8.88
Earnings Share
7.83
Revenue Per Share
60.641
Quarterly Revenue Growth
0.232
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.